Evidence map›Paper›PMID 28526957›Full record

ArticleAnnals of hematology2017

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.

Louise de Swart, Alex Smith, Marius MacKenzie, Argiris Symeonidis, Judith Neukirchen, Dana Mikulenková, Teresa Vallespí, Gina Zini, Malgorzata Paszkowska-Kowalewska, Anton Kruger and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 18 institutions in 13 countries.

Louise de SwartDepartment of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Alex SmithEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Marius MacKenzieDepartment of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Argiris SymeonidisDepartment of Medicine, Division of Haematology, University of Patras Medical School, Patras, Greece.
Judith NeukirchenDepartment of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany.
Dana MikulenkováDepartment of Clinical Haematology, Institution of Haematology and Blood Transfusion, Praha, Czech Republic.
Teresa VallespíDepartment of Haematology, Haematological Cytogenetics Unit, University Hospital of Vall d'Hebron, Barcelona, Spain.
Gina ZiniHaematology Institute, Catholic University of Sacred Heart, Rome, Italy.
Malgorzata Paszkowska-KowalewskaDepartment of Haematology, Oncology and Internal Medicine, Warszawa Medical University, Warszawa, Poland.
Anton KrugerDepartment of Haematology, Royal Cornwall Hospital, Truro, UK.
Leonie SaftDepartment of Pathology and Cytology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Pierre FenauxService d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France.
David BowenSt. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, UK.
Eva Hellström-LindbergDepartment of Medicine, Division of Haematology, Karolinska Institutet, Stockholm, Sweden.
Jaroslav ČermákDepartment of Clinical Haematology, Institution of Haematology and Blood Transfusion, Praha, Czech Republic.
Reinhard StauderDepartment of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.
Aurelia TaticCentre of Haematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Mette Skov HolmDepartment of Haematology, Aarhus University Hospital, Aarhus, Denmark.
Luca MalcovatiDepartment of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Krzysztof MądryDepartment of Haematology, Oncology and Internal Medicine, Warszawa Medical University, Warszawa, Poland.
Jackie DrosteDepartment of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Nicole BlijlevensDepartment of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Theo de WitteDepartment of Tumor Immunology - Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre (TIL, 278), P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands. Theo.deWitte@Radboudumc.nl.
Ulrich GermingDepartment of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany.
Radboud University Nijmegen · NLHeinrich Heine University Düsseldorf · DEInstitute of Haematology and Blood Transfusion · CZMedical University of Warsaw · PLAarhus University Hospital · DKAssistance Publique – Hôpitaux de Paris · FRInnsbruck Medical University · ATInstitutul Clinic Fundeni · ROIstituti di Ricovero e Cura a Carattere Scientifico · ITKarolinska Institutet · SEKarolinska University Hospital · SELeeds Teaching Hospitals NHS Trust · GBRadboud University Medical Center · NLRoyal Cornwall Hospital · GBUniversità Cattolica del Sacro Cuore · ITUniversity of Patras · GRUniversity of York · GBVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European LeukemiaNet MDS (EUMDS) registry is collecting data of myelodysplastic syndrome (MDS) patients belonging to the IPSS low or intermediate-1 category, newly diagnosed by local cytologists. The diagnosis of MDS can be challenging, and some data report inter-observer variability with regard to the assessment of the MDS subtype. In order to ensure that correct diagnoses were made by the participating centres, blood and bone marrow slides of 10% of the first 1000 patients were reviewed by an 11-person panel of cytomorphologists. All slides were rated by at least 3 panel members (median 8 panel members; range 3-9). Marrow slides from 98 out of 105 patients were of good quality and therefore could be rated properly according to the WHO 2001 classification, including assessment of dysplastic lineages. The agreement between the reviewers whether the diagnosis was MDS or non-MDS was strong with an intra-class correlation coefficient (ICC) of 0.85. Six cases were detected not to fit the entry criteria of the registry, because they were diagnosed uniformly as CMML or AML by the panel members. The agreement by WHO 2001 classification was strong as well (ICC = 0.83). The concordance of the assessment of dysplastic lineages was substantial for megakaryopoiesis and myelopoiesis and moderate for erythropoiesis. Our data show that in general, the inter-observer agreement was high and a very low percentage of misdiagnosed cases had been entered into the EUMDS registry. Further studies including histomorphology are warranted.

Indexed as

Observer VariationAdultAgedAged, 80 and overBone Marrow ExaminationCytodiagnosisFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesRegistriesReproducibility of ResultsSensitivity and SpecificityYoung AdultCytomorphology reviewDiagnosticsInter-observer variabilityMyelodysplastic syndromes (MDS)

Identifiers

PMID28526957
PMCPMC5486793
OpenAlexW2614726883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.